Cognition Therapeutics Inc CGTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026
-
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
-
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
-
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
-
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
-
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
Trading Information
- Previous Close Price
- $0.71
- Day Range
- $0.67–0.73
- 52-Week Range
- $0.55–1.83
- Bid/Ask
- $0.68 / $0.75
- Shares Outstanding
- 95.09M
- Market Cap
- $66.52M
- Volume/Avg
- 422,345 / 515,544
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 14
- Website
- https://www.cogrx.com
Valuation
|
Metric
|
CGTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.01 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CGTX
|
|---|---|
Quick Ratio | 6.78 |
Current Ratio | 7.03 |
Interest Coverage | −1,289.38 |
Quick Ratio
CGTX
Profitability
|
Metric
|
CGTX
|
|---|---|
Return on Assets (Normalized) | −40.89% |
Return on Equity (Normalized) | −54.15% |
Return on Invested Capital (Normalized) | −53.15% |
Return on Assets
CGTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<#k$N?@ | LOCK|&c^b | $135B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|l#DKYk | LOCK|xRP@$ | $101B | |||
| Moderna Inc
MRNA
| LOCK|^<vBXCr | LOCK|B$K | $91B | |||
| argenx SE ADR
ARGX
| LOCK|^$cq!%! | LOCK|r< | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|vTCLm> | LOCK|!<@ | $41B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|kKnmR>Z | LOCK|&<jsX | $30B | |||
| Incyte Corp
INCY
| LOCK|lQCMkr | LOCK|^$% | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|&VqxNwx | LOCK|HG> | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@PwFpB | LOCK|Ss>?! | $21B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|n@Zw!T | LOCK|T$ | $15B |
United States